ORGANIZATION
JPMA Chief Opposes Macroeconomic Indexing, Says Drugs Should Drive Economic Growth
Yasushi Okada, president of the Japan Pharmaceutical Manufacturers Association (JPMA), on September 21 expressed his opposition to the proposed introduction of “macroeconomic indexing,” which would set a cap on drug spending commensurate with the country’s economic growth. “If drug costs…
To read the full story
Related Article
ORGANIZATION
- Labor Group Urges Priority Supply of Petrochemical Products for Drug Manufacturing
May 15, 2026
- JPMA Launches New Legal Entity, Set for October Transition
May 1, 2026
- Regional Formularies Seen Driving Shift to Quality, Industry Consolidation: Society Head
April 27, 2026
- JPMA Mulls Proposal to Standardize PMDA Review Reports
April 27, 2026
- JPWA Urges Caution on Fixed Margins, Citing French Model Shortcomings
April 24, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…





